{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "%%capture\n",
    "# %pip install scrapegraphai\n",
    "%pip install scrapegraphai==1.20.0b1\n",
    "%apt install chromium-chromedriver\n",
    "%pip install nest_asyncio\n",
    "%pip install playwright\n",
    "%playwright install"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import nest_asyncio\n",
    "nest_asyncio.apply()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/Users/rateria/anaconda3/envs/cs-5787/lib/python3.9/site-packages/tqdm/auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "# sanity\n",
    "import json\n",
    "from openai import OpenAI\n",
    "from scrapegraphai.graphs import SmartScraperGraph\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "open_ai_key = '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'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load the CSV file\n",
    "df = pd.read_csv(\"categorized_content_links.csv\")\n",
    "\n",
    "column_name = \"url\"  # replace with the actual column name\n",
    "urls = df[column_name].dropna().unique().tolist()\n",
    "\n",
    "print(len(urls))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "# model schema\n",
    "from pydantic import BaseModel, Field\n",
    "from typing import Literal, List, Any"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "class PubHealthSchema(BaseModel):\n",
    "    supporting_claim: str\n",
    "    contradictory_claim: str\n",
    "    ambiguous_claim: str # 0: +ve, 1: -ve, 2: ambiguous \n",
    "    \n",
    "    def to_json(self):\n",
    "        return {\"supporting_claim\": self.supporting_claim, \"contradictory_claim\": self.contradictory_claim, \"ambiguous_claim\": self.ambiguous_claim}\n",
    "    \n",
    "class Schema(BaseModel):\n",
    "    claims: List[PubHealthSchema]\n",
    "    \n",
    "    def to_json(self):\n",
    "        return [data.to_json() for data in self.claims]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt = \"\"\"\n",
    "Use the data from this url to generate a group of claims and evidences according to the description below:\n",
    "\n",
    "Claim: A claim is an assertion or statement that proposes an idea, fact, or opinion. It is often the subject of verification, as it can contain elements that may be true, false, exaggerated, or misleading. Claims may require evidence or further investigation to determine their accuracy.\n",
    "\n",
    "Evidence: The evidence provides context, evidence, and clarification regarding the claim. It may include a breakdown of factual elements, highlight any inaccuracies, and explain nuances that help the reader understand the validity or implications of the claim. Explanations aim to inform by distinguishing between what is supported by evidence and what may be incorrect or misleading.\n",
    "\n",
    "Label: The label is a categorization of the claim after it has been evaluated. It often indicates the nature or degree of accuracy of the claim, such as whether it is true, false, partially true, misleading, or speculative. Labels help in classifying claims for easier identification and understanding of their reliability.\n",
    " \n",
    "Ensure that each claim is only one sentence long. Ensure that each evidence is NOT more than 4 sentences long. The values of the labels can be 0 or 1. 0 is when the evidence SUPPORTS the claim and 1 is when the evidence disproves the claim. Only generate claims which have the label of 1 for now.\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "ename": "ValidationError",
     "evalue": "1 validation error for Schema\ndata\n  Field required [type=missing, input_value={'src': 'https://sniv3r2....ions-to-seminal-plasma'}, input_type=dict]\n    For further information visit https://errors.pydantic.dev/2.9/v/missing",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mValidationError\u001b[0m                           Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[40], line 10\u001b[0m\n\u001b[1;32m      1\u001b[0m graph_config \u001b[38;5;241m=\u001b[39m {\n\u001b[1;32m      2\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mllm\u001b[39m\u001b[38;5;124m\"\u001b[39m: {\n\u001b[1;32m      3\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mapi_key\u001b[39m\u001b[38;5;124m\"\u001b[39m: open_ai_key,\n\u001b[0;32m   (...)\u001b[0m\n\u001b[1;32m      7\u001b[0m     \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mheadless\u001b[39m\u001b[38;5;124m\"\u001b[39m: \u001b[38;5;28;01mFalse\u001b[39;00m,\n\u001b[1;32m      8\u001b[0m }\n\u001b[0;32m---> 10\u001b[0m schema \u001b[38;5;241m=\u001b[39m \u001b[43mSchema\u001b[49m\u001b[43m(\u001b[49m\u001b[43msrc\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43murls\u001b[49m\u001b[43m[\u001b[49m\u001b[38;5;241;43m0\u001b[39;49m\u001b[43m]\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m     12\u001b[0m smart_scraper_graph \u001b[38;5;241m=\u001b[39m SmartScraperGraph(\n\u001b[1;32m     13\u001b[0m     prompt\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mprompt\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[1;32m     14\u001b[0m     source\u001b[38;5;241m=\u001b[39murls[\u001b[38;5;241m0\u001b[39m],\n\u001b[1;32m     15\u001b[0m     schema\u001b[38;5;241m=\u001b[39mschema,\n\u001b[1;32m     16\u001b[0m     config\u001b[38;5;241m=\u001b[39mgraph_config\n\u001b[1;32m     17\u001b[0m )\n\u001b[1;32m     19\u001b[0m result \u001b[38;5;241m=\u001b[39m smart_scraper_graph\u001b[38;5;241m.\u001b[39mrun()\n",
      "File \u001b[0;32m~/Code/cs-5787-final-project/.conda/lib/python3.9/site-packages/pydantic/main.py:212\u001b[0m, in \u001b[0;36mBaseModel.__init__\u001b[0;34m(self, **data)\u001b[0m\n\u001b[1;32m    210\u001b[0m \u001b[38;5;66;03m# `__tracebackhide__` tells pytest and some other tools to omit this function from tracebacks\u001b[39;00m\n\u001b[1;32m    211\u001b[0m __tracebackhide__ \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m--> 212\u001b[0m validated_self \u001b[38;5;241m=\u001b[39m \u001b[38;5;28;43mself\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m__pydantic_validator__\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mvalidate_python\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdata\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mself_instance\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mself\u001b[39;49m\u001b[43m)\u001b[49m\n\u001b[1;32m    213\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m validated_self:\n\u001b[1;32m    214\u001b[0m     warnings\u001b[38;5;241m.\u001b[39mwarn(\n\u001b[1;32m    215\u001b[0m         \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mA custom validator is returning a value other than `self`.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m'\u001b[39m\n\u001b[1;32m    216\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mReturning anything other than `self` from a top level model validator isn\u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124mt supported when validating via `__init__`.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    217\u001b[0m         \u001b[38;5;124m'\u001b[39m\u001b[38;5;124mSee the `model_validator` docs (https://docs.pydantic.dev/latest/concepts/validators/#model-validators) for more details.\u001b[39m\u001b[38;5;124m'\u001b[39m,\n\u001b[1;32m    218\u001b[0m         category\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mNone\u001b[39;00m,\n\u001b[1;32m    219\u001b[0m     )\n",
      "\u001b[0;31mValidationError\u001b[0m: 1 validation error for Schema\ndata\n  Field required [type=missing, input_value={'src': 'https://sniv3r2....ions-to-seminal-plasma'}, input_type=dict]\n    For further information visit https://errors.pydantic.dev/2.9/v/missing"
     ]
    }
   ],
   "source": [
    "graph_config = {\n",
    "    \"llm\": {\n",
    "        \"api_key\": open_ai_key,\n",
    "        \"model\": \"openai/gpt-4o-mini\",\n",
    "    },\n",
    "    \"verbose\": True,\n",
    "    \"headless\": False,\n",
    "}\n",
    "\n",
    "schema = Schema(src=urls[0])\n",
    "\n",
    "smart_scraper_graph = SmartScraperGraph(\n",
    "    prompt=\"prompt\",\n",
    "    source=urls[0],\n",
    "    schema=schema,\n",
    "    config=graph_config\n",
    ")\n",
    "\n",
    "result = smart_scraper_graph.run()\n",
    "print(result)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Output to CSV"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "def export_schema_to_csv(schema, file_name: str):    \n",
    "    # Create a DataFrame from the list of dictionaries\n",
    "    df = pd.DataFrame(schema['data'])\n",
    "    \n",
    "    # Export DataFrame to CSV\n",
    "    df.to_csv(file_name, index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [],
   "source": [
    "export_schema_to_csv(result, \"test-1.csv\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_prompt(num_samples):\n",
    "    prompt = f\"\"\"You are a medical expert. You will be given a medical document, generate three types of claims:\\n\\n1) A supporting claim that paraphrases a key assertion.\\n2) A contradictory claim that directly contradicts a key evidence provided in the summary.\\n3) An ambiguous claim that either partially supports or contradicts, or presents elements that are neither clearly supported nor contradicted.\\n\\nEach claim should be one or two sentences long. Ideally, the claims should be generated from different key assertions or sections of the summary.\\n\\nReturn ONLY the claims in this exact JSON format below. DO NOT include any extra text or explanations. DO NOT add ```json``` formatting. Just output the exact JSON as a string.\\n[{{\\n  \\\"supporting_claim\\\": '...',\\n  \\\"contradictory_claim\\\": '...',\\n  \\\"ambiguous_claim\\\": '...'\\n}}].\\n\\n Output {num_samples} triplets of supporting, contradictory, and ambiguous claims from the provided summary. Give all {num_samples} triplets in the same JSON array.\"\"\"\n",
    "    return prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "client = OpenAI(api_key=open_ai_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "text = open(\"./uptodate/1.txt\", \"r\").read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "completion = client.beta.chat.completions.parse(\n",
    "    model=\"gpt-4o-mini\",\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": get_prompt(20)},\n",
    "        {\"role\": \"user\", \"content\": f\"Document:\\n\\n{text}\"}\n",
    "    ],\n",
    "    response_format=Schema,\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'supporting_claim': 'UpToDate content is not meant to replace professional medical advice and should only be used as a supplementary source of information.',\n",
       "  'contradictory_claim': 'UpToDate is intended to provide definitive medical advice that can be solely relied upon for treatment decisions.',\n",
       "  'ambiguous_claim': 'While UpToDate offers extensive information on birth control methods, the effectiveness of these methods can vary significantly depending on individual circumstances.'},\n",
       " {'supporting_claim': 'IUDs and implants are among the most effective birth control methods due to their low risk of failure.',\n",
       "  'contradictory_claim': 'Contraceptives such as the condom and diaphragm are just as effective as long-term methods like IUDs.',\n",
       "  'ambiguous_claim': 'The effectiveness of birth control methods can greatly depend on how consistently and correctly they are used, leaving some uncertainty regarding their overall reliability.'},\n",
       " {'supporting_claim': 'Emergency contraception can be used up to five days after unprotected intercourse to decrease the chance of pregnancy.',\n",
       "  'contradictory_claim': 'Emergency contraception is only effective if used within 12 hours after unprotected sex.',\n",
       "  'ambiguous_claim': 'The availability of emergency contraception varies greatly depending on local regulations and individual pharmacy practices.'},\n",
       " {'supporting_claim': 'Consistent use of contraceptive methods is essential for maximizing their effectiveness in preventing pregnancy.',\n",
       "  'contradictory_claim': 'Utilizing any birth control method guarantees 100% protection against pregnancy if employed occasionally.',\n",
       "  'ambiguous_claim': 'While some contraceptive methods are reversible, the degree of effectiveness may change based on personal health conditions.'},\n",
       " {'supporting_claim': 'Birth control choices depend on personal and partner acceptability as well as potential side effects.',\n",
       "  'contradictory_claim': 'The choice of birth control method is entirely independent of side effects and personal preferences.',\n",
       "  'ambiguous_claim': 'Some women report more severe side effects with hormonal methods when compared to non-hormonal options, but experiences can differ widely.'},\n",
       " {'supporting_claim': 'Factors like cost, convenience, and side effects should all be considered when choosing a birth control method.',\n",
       "  'contradictory_claim': 'The cost of birth control methods has no impact on their effectiveness or accessibility.',\n",
       "  'ambiguous_claim': 'While methods like condoms and pills are widely available, how accessible they are can depend heavily on individual circumstances.'},\n",
       " {'supporting_claim': 'The birth control patch is as effective as traditional oral contraceptives but might be preferred for its ease of use.',\n",
       "  'contradictory_claim': 'Birth control patches are less effective than birth control pills, regardless of consistent usage.',\n",
       "  'ambiguous_claim': 'Although the birth control patch is recommended for its convenience, some women might have concerns about potential skin reactions.'},\n",
       " {'supporting_claim': 'Tubal ligation is a common procedure that provides permanent contraception for women.',\n",
       "  'contradictory_claim': 'Sterilization methods do not provide definitive long-term contraception and can be easily reversed.',\n",
       "  'ambiguous_claim': 'Sterilization is permanent, yet some women may experience regrets later on, leading to discussions about alternatives.'},\n",
       " {'supporting_claim': 'IUDs can be removed at any time, offering flexibility for women regarding their contraceptive choices.',\n",
       "  'contradictory_claim': 'Once an IUD is inserted, it cannot be removed until it naturally dislodges after many years.',\n",
       "  'ambiguous_claim': 'While IUDs are highly effective, user satisfaction may depend on managing potential discomfort during insertion.'},\n",
       " {'supporting_claim': 'Emergency contraceptive pills are less effective than the IUD when it comes to preventing pregnancy after unprotected intercourse.',\n",
       "  'contradictory_claim': 'Emergency contraceptive pills work as effectively as IUDs with no significant difference in outcomes.',\n",
       "  'ambiguous_claim': 'Despite being widely accessible, some women feel uncomfortable discussing or obtaining emergency contraception.'},\n",
       " {'supporting_claim': 'Barrier methods, like condoms, can also help reduce the transmission of sexually transmitted diseases.',\n",
       "  'contradictory_claim': 'Barrier methods do not offer any protection against STIs and should not be relied upon for that purpose.',\n",
       "  'ambiguous_claim': 'The effectiveness of barrier methods might be influenced by user technique and adherence to instructions.'},\n",
       " {'supporting_claim': 'Contrary to other forms of contraception, the birth control implant can be effective within 24 hours of insertion.',\n",
       "  'contradictory_claim': 'The birth control implant offers no protection against pregnancy until it has been in place for at least one month.',\n",
       "  'ambiguous_claim': 'While the birth control implant is known for its effectiveness, the experience of side effects can vary significantly among users.'},\n",
       " {'supporting_claim': 'Hormonal birth control methods can lead to a reduction in menstrual bleeding for many women.',\n",
       "  'contradictory_claim': 'Hormonal contraception always increases menstrual bleeding in every user without exception.',\n",
       "  'ambiguous_claim': 'Some women may prefer hormonal methods for the menstrual benefits, but may also experience unexpected side effects, leading to mixed reviews.'},\n",
       " {'supporting_claim': 'Consulting with a healthcare provider is essential for a thorough understanding of birth control options.',\n",
       "  'contradictory_claim': 'Reliable information on birth control methods can be exclusively found online without the need for professional guidance.',\n",
       "  'ambiguous_claim': 'The accessibility of professional medical advice can vary widely, influencing the decision-making process on birth control methods.'},\n",
       " {'supporting_claim': 'Studies indicate that many women stop having periods entirely after using certain IUDs for a year.',\n",
       "  'contradictory_claim': 'Using IUDs consistently guarantees that all women will continue to have regular menstrual cycles.',\n",
       "  'ambiguous_claim': 'While many report stopping menstruation with an IUD, individual hormonal responses can lead to differing experiences.'},\n",
       " {'supporting_claim': 'Women using medroxyprogesterone acetate (DMPA) may experience irregular bleeding as a common side effect during the first months.',\n",
       "  'contradictory_claim': 'DMPA users do not report any side effects, including irregular bleeding or spotting.',\n",
       "  'ambiguous_claim': 'Although DMPA has proven effectiveness, the inconsistency of menstrual cycles can be a significant concern for some women.'},\n",
       " {'supporting_claim': 'The content on UpToDate assists individuals in making informed choices regarding their birth control options.',\n",
       "  'contradictory_claim': 'Consulting UpToDate is sufficient to make definitive decisions on contraceptive methods without additional resources.',\n",
       "  'ambiguous_claim': 'While UpToDate provides a wealth of information on birth control, the interpretation of this information may vary widely among different users.'},\n",
       " {'supporting_claim': 'Natural family planning methods require careful monitoring of physiological changes to accurately identify fertile days.',\n",
       "  'contradictory_claim': 'Natural family planning methods can be employed without any monitoring or knowledge of menstrual cycles.',\n",
       "  'ambiguous_claim': 'The reliance on natural family planning could make it less effective for those with irregular cycles, raising questions about its reliability.'}]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "completion.choices[0].message.parsed.to_json()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Semantic Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/sn/h8k80m7j0wx704gsf17nmqmm0000gn/T/ipykernel_23689/4272845173.py:2: LangChainDeprecationWarning: The class `OpenAIEmbeddings` was deprecated in LangChain 0.0.9 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-openai package and should be used instead. To use it run `pip install -U :class:`~langchain-openai` and import as `from :class:`~langchain_openai import OpenAIEmbeddings``.\n",
      "  oaiembeds = OpenAIEmbeddings(openai_api_key=\"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\")\n"
     ]
    }
   ],
   "source": [
    "from langchain.embeddings import OpenAIEmbeddings\n",
    "oaiembeds = OpenAIEmbeddings(openai_api_key=\"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\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open(\"./UTD2txt/10.txt\") as f:\n",
    "    text = f.read()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\\nHypersensitivity reactions:\\nSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.\\nAbacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible.\\nFollowing a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity.\\nHematologic toxicity:\\nZidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.\\nMyopathy:\\nProlonged use of zidovudine has been associated with symptomatic myopathy.\\nLactic acidosis and severe hepatomegaly with steatosis:\\nLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.\\nExacerbations of hepatitis B:\\nSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of anti-HBV therapy may be warranted.\\nBrand Names: US\\nTrizivir\\nBrand Names: Canada\\nPharmacologic Category\\nAntiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\\nDosing: Adult\\nHIV-1 infection, treatment: Oral: One tablet twice daily.\\nDosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\\nHIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing. Note: Not recommended for pediatric patients <40 kg.\\nDosing: Geriatric\\nRefer to adult dosing.\\nDosing: Renal Impairment\\nCrCl ≥50 mL/minute: No dosage adjustment necessary.\\nCrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components).\\nDosing: Hepatic Impairment\\nMild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components).\\nModerate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated.\\nDosage Forms\\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling.\\nTablet, Oral:\\nTrizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\\nGeneric: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\\nGeneric Equivalent Available (US)\\nYes\\nMedication Guide and/or Vaccine Information Statement (VIS)\\nAn FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.\\nAdministration\\nAdminister without regard to food.\\nHazardous Drugs Handling Considerations\\nHazardous agent (NIOSH 2016 [group 2]).\\nAbacavir is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).\\nUse\\nHIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents.\\nLimitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL).\\nMedication Safety Issues\\nHigh alert medication:\\nThis medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.\\nAdverse Reactions\\nSee individual agents as well as other combination products for additional information. Frequency not always defined.\\nCentral nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\\nDermatologic: Skin rash (5%)\\nEndocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\\nGastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\\nHematologic & oncologic: Neutropenia (5%)\\nHepatic: Increased serum ALT (6%)\\nHypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\\nImmunologic: Immune reconstitution syndrome\\nInfection: Viral infection (5%)\\nMiscellaneous: Fever and chills (6%)\\nNeuromuscular & skeletal: Increased creatine phosphokinase (7%)\\nRespiratory: ENT infection (5%)\\n<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\\nContraindications\\nHypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment.\\nCanadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\\nWarnings/Precautions\\nConcerns related to adverse effects:\\n• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).\\n• Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL). Frequent complete blood counts are recommended in patients with advanced HIV-1 disease. Dosage interruption may be needed if anemia or neutropenia develops.\\n• Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir). Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment. Discontinue Trizivir if a hypersensitivity reaction is suspected. Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir. Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy. Such reactions can occur within hours. Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record. Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2015). These reactions usually include signs or symptoms in 2 or more of the following groups: fever; rash; gastrointestinal (eg, nausea, vomiting, diarrhea, abdominal pain); constitutional (eg, generalized malaise, fatigue, achiness); respiratory (eg, dyspnea, cough, pharyngitis). Other signs and symptoms include lethargy, headache, myalgia, edema, abnormal chest x-ray findings, arthralgia and paresthesia. Anaphylaxis, liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, myolysis, and death have occurred in association with hypersensitivity reactions. Physical findings (lymphadenopathy, mucous membrane lesions, and rash [maculopapular, urticarial or variable]) may occur. Erythema multiforme has also been reported. Laboratory abnormalities (eg, elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia) may occur. Trizivir should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible. Following a hypersensitivity reaction, Trizivir SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH. If Trizivir is to be restarted following an interruption in therapy not associated with symptoms of a hypersensitivity reaction, carefully evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or cannot be ruled out regardless of HLA-B*5701 status. If Trizivir is restarted, continually monitor for symptoms of a hypersensitivity reaction. Make the patient aware that reintroduction should only take place if medical care is readily accessible.\\n• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves’ disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.\\n• Lactic acidosis/hepatomegaly: [US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues; use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).\\n• Myopathy: [US Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy and myositis.\\n• Pancreatitis: Pancreatitis has been observed with abacavir, lamivudine and zidovudine; rule out pancreatitis in patients who develop signs/symptoms (eg, nausea/vomiting, abdominal pain, elevated lipase and amylase) during therapy.\\nDisease-related concerns:\\n• Chronic hepatitis B: [US Boxed Warning]: Exacerbation of hepatitis B (including fatalities) has been reported with discontinuation of lamivudine in coinfected HIV/HBV patients; monitor hepatic function (eg, serum ALT) and HBV viral DNA closely for several months after discontinuing Trizivir in coinfected patients.\\n• Coronary heart disease: Use has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.\\n• Lamivudine-resistant HBV: Emergence of HBV virus variants associated with resistance to lamivudine have been reported in HIV-1 infected subjects who have received lamivudine-containing antiretroviral regimens in the presence of HBV coinfection.\\n• Renal impairment: Trizivir, as a fixed-dose combination tablet, should not be used in patients with CrCl <50 mL/minute.\\nConcurrent drug therapy issues:\\n• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.\\nSpecial populations:\\n• Pediatric patients <40 kg: Trizivir, as a fixed-dose combination tablet, should not be used in patients <40 kg or those requiring dosage adjustment.\\n• Therapy-experienced patients: Patients with prolonged prior nucleoside reverse transcriptase inhibitor (NRTI) exposure or presence of HIV-1 isolates containing multiple mutations conferring resistance to NRTIs have limited response to abacavir. The potential for cross resistance between abacavir and other NRTIs should be considered when evaluating new regimens in therapy experienced patients.\\nMetabolism/Transport Effects\\nRefer to individual components.\\nDrug Interactions (For additional information: Launch drug interactions program) Acemetacin: May enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for hematologic toxicity may be increased. Risk C: Monitor therapy\\nAcyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine. Risk C: Monitor therapy\\nAmodiaquine: Zidovudine may enhance the neutropenic effect of Amodiaquine. Risk X: Avoid combination\\nBCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination\\nCabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Risk C: Monitor therapy\\nChloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy\\nClarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction. Risk D: Consider therapy modification\\nCloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy\\nDeferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Risk X: Avoid combination\\nDexketoprofen: May enhance the adverse/toxic effect of Zidovudine. Risk C: Monitor therapy\\nTrimethoprim: May increase the serum concentration of LamiVUDine. Risk C: Monitor therapy\\nValproate Products: May increase the serum concentration of Zidovudine. Risk C: Monitor therapy\\nFood Interactions\\nEthanol decreases the elimination of abacavir and may increase the risk of toxicity. Management: Monitor patients.\\nPregnancy Implications\\nThe Health and Human Services (HHS) Perinatal HIV Guidelines generally do not recommend this combination as initial therapy in antiretroviral-naive pregnant females due to inferior virologic activity. However, females who become pregnant on this regimen, in absence of other antiretroviral medications, may continue if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated (HHS [perinatal] 2017). See individual agents.\\nBreast-Feeding Considerations\\nAbacavir, lamivudine, and zidovudine are present in breast milk. See individual agents.\\nMonitoring Parameters\\nBlood glucose, CBC with differential, serum creatine kinase, CD4 count, HIV RNA plasma levels, bilirubin, serum transaminases, triglycerides, serum amylase; HLA-B*5701 genotype status prior to initiation of therapy and prior to reinitiation of therapy in patients of unknown HLA-B*5701 status; signs and symptoms of hypersensitivity, particularly in patients untested for the HLA-B*5701 allele; signs and symptoms of pancreatitis; observe for appearance of opportunistic infections\\nMechanism of Action\\nThe combination of abacavir, lamivudine, and zidovudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance.\\nPharmacodynamics/Kinetics\\nBioavailability studies of Trizivir® show no difference in AUC or Cmax when compared to abacavir, lamivudine, and zidovudine given together as individual agents. See individual agents.\\nPricing: US\\nTablets (Abacavir-Lamivudine-Zidovudine Oral)\\n300-150-300 mg (60): $1,738.46'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "104 senteneces were found\n"
     ]
    }
   ],
   "source": [
    "import re\n",
    "\n",
    "# Splitting the essay on '.', '?', and '!'\n",
    "single_sentences_list = re.split(r'(?<=[.?!])\\s+', text)\n",
    "print (f\"{len(single_sentences_list)} senteneces were found\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\\nHypersensitivity reactions:\\nSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir.',\n",
       " 'Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.',\n",
       " 'Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients.',\n",
       " 'All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment.',\n",
       " 'Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible.',\n",
       " 'Following a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours.',\n",
       " 'Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity.',\n",
       " 'Hematologic toxicity:\\nZidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.',\n",
       " 'Myopathy:\\nProlonged use of zidovudine has been associated with symptomatic myopathy.',\n",
       " 'Lactic acidosis and severe hepatomegaly with steatosis:\\nLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals.',\n",
       " 'Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.',\n",
       " 'Exacerbations of hepatitis B:\\nSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine.',\n",
       " 'Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV.',\n",
       " 'If appropriate, initiation of anti-HBV therapy may be warranted.',\n",
       " 'Brand Names: US\\nTrizivir\\nBrand Names: Canada\\nPharmacologic Category\\nAntiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\\nDosing: Adult\\nHIV-1 infection, treatment: Oral: One tablet twice daily.',\n",
       " 'Dosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\\nHIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing.',\n",
       " 'Note: Not recommended for pediatric patients <40 kg.',\n",
       " 'Dosing: Geriatric\\nRefer to adult dosing.',\n",
       " 'Dosing: Renal Impairment\\nCrCl ≥50 mL/minute: No dosage adjustment necessary.',\n",
       " 'CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components).',\n",
       " 'Dosing: Hepatic Impairment\\nMild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components).',\n",
       " 'Moderate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated.',\n",
       " 'Dosage Forms\\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling.',\n",
       " 'Tablet, Oral:\\nTrizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\\nGeneric: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\\nGeneric Equivalent Available (US)\\nYes\\nMedication Guide and/or Vaccine Information Statement (VIS)\\nAn FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication.',\n",
       " 'A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.',\n",
       " 'Administration\\nAdminister without regard to food.',\n",
       " 'Hazardous Drugs Handling Considerations\\nHazardous agent (NIOSH 2016 [group 2]).',\n",
       " 'Abacavir is a hazardous agent.',\n",
       " 'Use appropriate precautions for receiving, handling, administration, and disposal.',\n",
       " 'Gloves (single) should be worn during receiving, unpacking, and placing in storage.',\n",
       " 'NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).',\n",
       " 'Use\\nHIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents.',\n",
       " 'Limitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL).',\n",
       " 'Medication Safety Issues\\nHigh alert medication:\\nThis medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.',\n",
       " 'Adverse Reactions\\nSee individual agents as well as other combination products for additional information.',\n",
       " 'Frequency not always defined.',\n",
       " 'Central nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\\nDermatologic: Skin rash (5%)\\nEndocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\\nGastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\\nHematologic & oncologic: Neutropenia (5%)\\nHepatic: Increased serum ALT (6%)\\nHypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\\nImmunologic: Immune reconstitution syndrome\\nInfection: Viral infection (5%)\\nMiscellaneous: Fever and chills (6%)\\nNeuromuscular & skeletal: Increased creatine phosphokinase (7%)\\nRespiratory: ENT infection (5%)\\n<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\\nContraindications\\nHypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment.',\n",
       " 'Canadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\\nWarnings/Precautions\\nConcerns related to adverse effects:\\n• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).',\n",
       " '• Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL).',\n",
       " 'Frequent complete blood counts are recommended in patients with advanced HIV-1 disease.',\n",
       " 'Dosage interruption may be needed if anemia or neutropenia develops.',\n",
       " '• Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir).',\n",
       " 'Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.',\n",
       " 'All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment.',\n",
       " 'Discontinue Trizivir if a hypersensitivity reaction is suspected.',\n",
       " 'Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir.',\n",
       " 'Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy.',\n",
       " 'Such reactions can occur within hours.',\n",
       " 'Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record.',\n",
       " 'Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2015).',\n",
       " 'These reactions usually include signs or symptoms in 2 or more of the following groups: fever; rash; gastrointestinal (eg, nausea, vomiting, diarrhea, abdominal pain); constitutional (eg, generalized malaise, fatigue, achiness); respiratory (eg, dyspnea, cough, pharyngitis).',\n",
       " 'Other signs and symptoms include lethargy, headache, myalgia, edema, abnormal chest x-ray findings, arthralgia and paresthesia.',\n",
       " 'Anaphylaxis, liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, myolysis, and death have occurred in association with hypersensitivity reactions.',\n",
       " 'Physical findings (lymphadenopathy, mucous membrane lesions, and rash [maculopapular, urticarial or variable]) may occur.',\n",
       " 'Erythema multiforme has also been reported.',\n",
       " 'Laboratory abnormalities (eg, elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia) may occur.',\n",
       " 'Trizivir should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible.',\n",
       " 'Following a hypersensitivity reaction, Trizivir SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH.',\n",
       " 'If Trizivir is to be restarted following an interruption in therapy not associated with symptoms of a hypersensitivity reaction, carefully evaluate the patient for previously unsuspected symptoms of hypersensitivity.',\n",
       " 'Do not restart if hypersensitivity is suspected or cannot be ruled out regardless of HLA-B*5701 status.',\n",
       " 'If Trizivir is restarted, continually monitor for symptoms of a hypersensitivity reaction.',\n",
       " 'Make the patient aware that reintroduction should only take place if medical care is readily accessible.',\n",
       " '• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves’ disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required.',\n",
       " '• Lactic acidosis/hepatomegaly: [US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues; use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).',\n",
       " '• Myopathy: [US Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy and myositis.',\n",
       " '• Pancreatitis: Pancreatitis has been observed with abacavir, lamivudine and zidovudine; rule out pancreatitis in patients who develop signs/symptoms (eg, nausea/vomiting, abdominal pain, elevated lipase and amylase) during therapy.',\n",
       " 'Disease-related concerns:\\n• Chronic hepatitis B: [US Boxed Warning]: Exacerbation of hepatitis B (including fatalities) has been reported with discontinuation of lamivudine in coinfected HIV/HBV patients; monitor hepatic function (eg, serum ALT) and HBV viral DNA closely for several months after discontinuing Trizivir in coinfected patients.',\n",
       " '• Coronary heart disease: Use has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials, the FDA has concluded there is not an increased risk.',\n",
       " 'Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use.',\n",
       " '• Lamivudine-resistant HBV: Emergence of HBV virus variants associated with resistance to lamivudine have been reported in HIV-1 infected subjects who have received lamivudine-containing antiretroviral regimens in the presence of HBV coinfection.',\n",
       " '• Renal impairment: Trizivir, as a fixed-dose combination tablet, should not be used in patients with CrCl <50 mL/minute.',\n",
       " 'Concurrent drug therapy issues:\\n• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy.',\n",
       " 'Consult drug interactions database for more detailed information.',\n",
       " 'Special populations:\\n• Pediatric patients <40 kg: Trizivir, as a fixed-dose combination tablet, should not be used in patients <40 kg or those requiring dosage adjustment.',\n",
       " '• Therapy-experienced patients: Patients with prolonged prior nucleoside reverse transcriptase inhibitor (NRTI) exposure or presence of HIV-1 isolates containing multiple mutations conferring resistance to NRTIs have limited response to abacavir.',\n",
       " 'The potential for cross resistance between abacavir and other NRTIs should be considered when evaluating new regimens in therapy experienced patients.',\n",
       " 'Metabolism/Transport Effects\\nRefer to individual components.',\n",
       " 'Drug Interactions (For additional information: Launch drug interactions program) Acemetacin: May enhance the adverse/toxic effect of Zidovudine.',\n",
       " 'Specifically, the risk for hematologic toxicity may be increased.',\n",
       " 'Risk C: Monitor therapy\\nAcyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine.',\n",
       " 'Risk C: Monitor therapy\\nAmodiaquine: Zidovudine may enhance the neutropenic effect of Amodiaquine.',\n",
       " 'Risk X: Avoid combination\\nBCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical).',\n",
       " 'Risk X: Avoid combination\\nCabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib.',\n",
       " 'Risk C: Monitor therapy\\nChloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.',\n",
       " 'Risk C: Monitor therapy\\nClarithromycin: May enhance the myelosuppressive effect of Zidovudine.',\n",
       " 'Clarithromycin may decrease the serum concentration of Zidovudine.',\n",
       " 'Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.',\n",
       " 'Risk D: Consider therapy modification\\nCloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine.',\n",
       " 'Specifically, the risk for neutropenia may be increased.',\n",
       " 'Risk C: Monitor therapy\\nDeferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.',\n",
       " 'Risk X: Avoid combination\\nDexketoprofen: May enhance the adverse/toxic effect of Zidovudine.',\n",
       " 'Risk C: Monitor therapy\\nTrimethoprim: May increase the serum concentration of LamiVUDine.',\n",
       " 'Risk C: Monitor therapy\\nValproate Products: May increase the serum concentration of Zidovudine.',\n",
       " 'Risk C: Monitor therapy\\nFood Interactions\\nEthanol decreases the elimination of abacavir and may increase the risk of toxicity.',\n",
       " 'Management: Monitor patients.',\n",
       " 'Pregnancy Implications\\nThe Health and Human Services (HHS) Perinatal HIV Guidelines generally do not recommend this combination as initial therapy in antiretroviral-naive pregnant females due to inferior virologic activity.',\n",
       " 'However, females who become pregnant on this regimen, in absence of other antiretroviral medications, may continue if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated (HHS [perinatal] 2017).',\n",
       " 'See individual agents.',\n",
       " 'Breast-Feeding Considerations\\nAbacavir, lamivudine, and zidovudine are present in breast milk.',\n",
       " 'See individual agents.',\n",
       " 'Monitoring Parameters\\nBlood glucose, CBC with differential, serum creatine kinase, CD4 count, HIV RNA plasma levels, bilirubin, serum transaminases, triglycerides, serum amylase; HLA-B*5701 genotype status prior to initiation of therapy and prior to reinitiation of therapy in patients of unknown HLA-B*5701 status; signs and symptoms of hypersensitivity, particularly in patients untested for the HLA-B*5701 allele; signs and symptoms of pancreatitis; observe for appearance of opportunistic infections\\nMechanism of Action\\nThe combination of abacavir, lamivudine, and zidovudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance.',\n",
       " 'Pharmacodynamics/Kinetics\\nBioavailability studies of Trizivir® show no difference in AUC or Cmax when compared to abacavir, lamivudine, and zidovudine given together as individual agents.',\n",
       " 'See individual agents.',\n",
       " 'Pricing: US\\nTablets (Abacavir-Lamivudine-Zidovudine Oral)\\n300-150-300 mg (60): $1,738.46']"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "single_sentences_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'sentence': 'Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\\nHypersensitivity reactions:\\nSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir.',\n",
       "  'index': 0},\n",
       " {'sentence': 'Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.',\n",
       "  'index': 1},\n",
       " {'sentence': 'Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients.',\n",
       "  'index': 2}]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences = [{'sentence': x, 'index' : i} for i, x in enumerate(single_sentences_list)]\n",
    "sentences[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "def combine_sentences(sentences, buffer_size=1):\n",
    "    # Go through each sentence dict\n",
    "    for i in range(len(sentences)):\n",
    "\n",
    "        # Create a string that will hold the sentences which are joined\n",
    "        combined_sentence = ''\n",
    "\n",
    "        # Add sentences before the current one, based on the buffer size.\n",
    "        for j in range(i - buffer_size, i):\n",
    "            # Check if the index j is not negative (to avoid index out of range like on the first one)\n",
    "            if j >= 0:\n",
    "                # Add the sentence at index j to the combined_sentence string\n",
    "                combined_sentence += sentences[j]['sentence'] + ' '\n",
    "\n",
    "        # Add the current sentence\n",
    "        combined_sentence += sentences[i]['sentence']\n",
    "\n",
    "        # Add sentences after the current one, based on the buffer size\n",
    "        for j in range(i + 1, i + 1 + buffer_size):\n",
    "            # Check if the index j is within the range of the sentences list\n",
    "            if j < len(sentences):\n",
    "                # Add the sentence at index j to the combined_sentence string\n",
    "                combined_sentence += ' ' + sentences[j]['sentence']\n",
    "\n",
    "        # Then add the whole thing to your dict\n",
    "        # Store the combined sentence in the current sentence dict\n",
    "        sentences[i]['combined_sentence'] = combined_sentence\n",
    "\n",
    "    return sentences\n",
    "\n",
    "sentences = combine_sentences(sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'sentence': 'Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\\nHypersensitivity reactions:\\nSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir.',\n",
       "  'index': 0,\n",
       "  'combined_sentence': 'Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\\nHypersensitivity reactions:\\nSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.'},\n",
       " {'sentence': 'Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.',\n",
       "  'index': 1,\n",
       "  'combined_sentence': 'Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\\nHypersensitivity reactions:\\nSerious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients.'},\n",
       " {'sentence': 'Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients.',\n",
       "  'index': 2,\n",
       "  'combined_sentence': 'Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment.'},\n",
       " {'sentence': 'All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment.',\n",
       "  'index': 3,\n",
       "  'combined_sentence': 'Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible.'},\n",
       " {'sentence': 'Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible.',\n",
       "  'index': 4,\n",
       "  'combined_sentence': 'All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible. Following a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours.'},\n",
       " {'sentence': 'Following a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours.',\n",
       "  'index': 5,\n",
       "  'combined_sentence': 'Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible. Following a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity.'},\n",
       " {'sentence': 'Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity.',\n",
       "  'index': 6,\n",
       "  'combined_sentence': 'Following a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity. Hematologic toxicity:\\nZidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.'},\n",
       " {'sentence': 'Hematologic toxicity:\\nZidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease.',\n",
       "  'index': 7,\n",
       "  'combined_sentence': 'Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity. Hematologic toxicity:\\nZidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease. Myopathy:\\nProlonged use of zidovudine has been associated with symptomatic myopathy.'},\n",
       " {'sentence': 'Myopathy:\\nProlonged use of zidovudine has been associated with symptomatic myopathy.',\n",
       "  'index': 8,\n",
       "  'combined_sentence': 'Hematologic toxicity:\\nZidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease. Myopathy:\\nProlonged use of zidovudine has been associated with symptomatic myopathy. Lactic acidosis and severe hepatomegaly with steatosis:\\nLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals.'},\n",
       " {'sentence': 'Lactic acidosis and severe hepatomegaly with steatosis:\\nLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals.',\n",
       "  'index': 9,\n",
       "  'combined_sentence': 'Myopathy:\\nProlonged use of zidovudine has been associated with symptomatic myopathy. Lactic acidosis and severe hepatomegaly with steatosis:\\nLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.'},\n",
       " {'sentence': 'Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.',\n",
       "  'index': 10,\n",
       "  'combined_sentence': 'Lactic acidosis and severe hepatomegaly with steatosis:\\nLactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. Exacerbations of hepatitis B:\\nSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine.'},\n",
       " {'sentence': 'Exacerbations of hepatitis B:\\nSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine.',\n",
       "  'index': 11,\n",
       "  'combined_sentence': 'Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. Exacerbations of hepatitis B:\\nSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV.'},\n",
       " {'sentence': 'Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV.',\n",
       "  'index': 12,\n",
       "  'combined_sentence': 'Exacerbations of hepatitis B:\\nSevere acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of anti-HBV therapy may be warranted.'},\n",
       " {'sentence': 'If appropriate, initiation of anti-HBV therapy may be warranted.',\n",
       "  'index': 13,\n",
       "  'combined_sentence': 'Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV. If appropriate, initiation of anti-HBV therapy may be warranted. Brand Names: US\\nTrizivir\\nBrand Names: Canada\\nPharmacologic Category\\nAntiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\\nDosing: Adult\\nHIV-1 infection, treatment: Oral: One tablet twice daily.'},\n",
       " {'sentence': 'Brand Names: US\\nTrizivir\\nBrand Names: Canada\\nPharmacologic Category\\nAntiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\\nDosing: Adult\\nHIV-1 infection, treatment: Oral: One tablet twice daily.',\n",
       "  'index': 14,\n",
       "  'combined_sentence': 'If appropriate, initiation of anti-HBV therapy may be warranted. Brand Names: US\\nTrizivir\\nBrand Names: Canada\\nPharmacologic Category\\nAntiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\\nDosing: Adult\\nHIV-1 infection, treatment: Oral: One tablet twice daily. Dosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\\nHIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing.'},\n",
       " {'sentence': 'Dosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\\nHIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing.',\n",
       "  'index': 15,\n",
       "  'combined_sentence': 'Brand Names: US\\nTrizivir\\nBrand Names: Canada\\nPharmacologic Category\\nAntiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\\nDosing: Adult\\nHIV-1 infection, treatment: Oral: One tablet twice daily. Dosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\\nHIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing. Note: Not recommended for pediatric patients <40 kg.'},\n",
       " {'sentence': 'Note: Not recommended for pediatric patients <40 kg.',\n",
       "  'index': 16,\n",
       "  'combined_sentence': 'Dosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\\nHIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing. Note: Not recommended for pediatric patients <40 kg. Dosing: Geriatric\\nRefer to adult dosing.'},\n",
       " {'sentence': 'Dosing: Geriatric\\nRefer to adult dosing.',\n",
       "  'index': 17,\n",
       "  'combined_sentence': 'Note: Not recommended for pediatric patients <40 kg. Dosing: Geriatric\\nRefer to adult dosing. Dosing: Renal Impairment\\nCrCl ≥50 mL/minute: No dosage adjustment necessary.'},\n",
       " {'sentence': 'Dosing: Renal Impairment\\nCrCl ≥50 mL/minute: No dosage adjustment necessary.',\n",
       "  'index': 18,\n",
       "  'combined_sentence': 'Dosing: Geriatric\\nRefer to adult dosing. Dosing: Renal Impairment\\nCrCl ≥50 mL/minute: No dosage adjustment necessary. CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components).'},\n",
       " {'sentence': 'CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components).',\n",
       "  'index': 19,\n",
       "  'combined_sentence': 'Dosing: Renal Impairment\\nCrCl ≥50 mL/minute: No dosage adjustment necessary. CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components). Dosing: Hepatic Impairment\\nMild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components).'},\n",
       " {'sentence': 'Dosing: Hepatic Impairment\\nMild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components).',\n",
       "  'index': 20,\n",
       "  'combined_sentence': 'CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components). Dosing: Hepatic Impairment\\nMild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components). Moderate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated.'},\n",
       " {'sentence': 'Moderate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated.',\n",
       "  'index': 21,\n",
       "  'combined_sentence': 'Dosing: Hepatic Impairment\\nMild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components). Moderate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated. Dosage Forms\\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling.'},\n",
       " {'sentence': 'Dosage Forms\\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling.',\n",
       "  'index': 22,\n",
       "  'combined_sentence': 'Moderate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated. Dosage Forms\\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling. Tablet, Oral:\\nTrizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\\nGeneric: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\\nGeneric Equivalent Available (US)\\nYes\\nMedication Guide and/or Vaccine Information Statement (VIS)\\nAn FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication.'},\n",
       " {'sentence': 'Tablet, Oral:\\nTrizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\\nGeneric: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\\nGeneric Equivalent Available (US)\\nYes\\nMedication Guide and/or Vaccine Information Statement (VIS)\\nAn FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication.',\n",
       "  'index': 23,\n",
       "  'combined_sentence': 'Dosage Forms\\nExcipient information presented when available (limited, particularly for generics); consult specific product labeling. Tablet, Oral:\\nTrizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\\nGeneric: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\\nGeneric Equivalent Available (US)\\nYes\\nMedication Guide and/or Vaccine Information Statement (VIS)\\nAn FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.'},\n",
       " {'sentence': 'A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.',\n",
       "  'index': 24,\n",
       "  'combined_sentence': 'Tablet, Oral:\\nTrizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\\nGeneric: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\\nGeneric Equivalent Available (US)\\nYes\\nMedication Guide and/or Vaccine Information Statement (VIS)\\nAn FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill. Administration\\nAdminister without regard to food.'},\n",
       " {'sentence': 'Administration\\nAdminister without regard to food.',\n",
       "  'index': 25,\n",
       "  'combined_sentence': 'A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill. Administration\\nAdminister without regard to food. Hazardous Drugs Handling Considerations\\nHazardous agent (NIOSH 2016 [group 2]).'},\n",
       " {'sentence': 'Hazardous Drugs Handling Considerations\\nHazardous agent (NIOSH 2016 [group 2]).',\n",
       "  'index': 26,\n",
       "  'combined_sentence': 'Administration\\nAdminister without regard to food. Hazardous Drugs Handling Considerations\\nHazardous agent (NIOSH 2016 [group 2]). Abacavir is a hazardous agent.'},\n",
       " {'sentence': 'Abacavir is a hazardous agent.',\n",
       "  'index': 27,\n",
       "  'combined_sentence': 'Hazardous Drugs Handling Considerations\\nHazardous agent (NIOSH 2016 [group 2]). Abacavir is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal.'},\n",
       " {'sentence': 'Use appropriate precautions for receiving, handling, administration, and disposal.',\n",
       "  'index': 28,\n",
       "  'combined_sentence': 'Abacavir is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.'},\n",
       " {'sentence': 'Gloves (single) should be worn during receiving, unpacking, and placing in storage.',\n",
       "  'index': 29,\n",
       "  'combined_sentence': 'Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).'},\n",
       " {'sentence': 'NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).',\n",
       "  'index': 30,\n",
       "  'combined_sentence': 'Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Use\\nHIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents.'},\n",
       " {'sentence': 'Use\\nHIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents.',\n",
       "  'index': 31,\n",
       "  'combined_sentence': 'NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Use\\nHIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents. Limitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL).'},\n",
       " {'sentence': 'Limitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL).',\n",
       "  'index': 32,\n",
       "  'combined_sentence': 'Use\\nHIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents. Limitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL). Medication Safety Issues\\nHigh alert medication:\\nThis medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.'},\n",
       " {'sentence': 'Medication Safety Issues\\nHigh alert medication:\\nThis medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.',\n",
       "  'index': 33,\n",
       "  'combined_sentence': 'Limitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL). Medication Safety Issues\\nHigh alert medication:\\nThis medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. Adverse Reactions\\nSee individual agents as well as other combination products for additional information.'},\n",
       " {'sentence': 'Adverse Reactions\\nSee individual agents as well as other combination products for additional information.',\n",
       "  'index': 34,\n",
       "  'combined_sentence': 'Medication Safety Issues\\nHigh alert medication:\\nThis medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. Adverse Reactions\\nSee individual agents as well as other combination products for additional information. Frequency not always defined.'},\n",
       " {'sentence': 'Frequency not always defined.',\n",
       "  'index': 35,\n",
       "  'combined_sentence': 'Adverse Reactions\\nSee individual agents as well as other combination products for additional information. Frequency not always defined. Central nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\\nDermatologic: Skin rash (5%)\\nEndocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\\nGastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\\nHematologic & oncologic: Neutropenia (5%)\\nHepatic: Increased serum ALT (6%)\\nHypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\\nImmunologic: Immune reconstitution syndrome\\nInfection: Viral infection (5%)\\nMiscellaneous: Fever and chills (6%)\\nNeuromuscular & skeletal: Increased creatine phosphokinase (7%)\\nRespiratory: ENT infection (5%)\\n<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\\nContraindications\\nHypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment.'},\n",
       " {'sentence': 'Central nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\\nDermatologic: Skin rash (5%)\\nEndocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\\nGastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\\nHematologic & oncologic: Neutropenia (5%)\\nHepatic: Increased serum ALT (6%)\\nHypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\\nImmunologic: Immune reconstitution syndrome\\nInfection: Viral infection (5%)\\nMiscellaneous: Fever and chills (6%)\\nNeuromuscular & skeletal: Increased creatine phosphokinase (7%)\\nRespiratory: ENT infection (5%)\\n<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\\nContraindications\\nHypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment.',\n",
       "  'index': 36,\n",
       "  'combined_sentence': 'Frequency not always defined. Central nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\\nDermatologic: Skin rash (5%)\\nEndocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\\nGastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\\nHematologic & oncologic: Neutropenia (5%)\\nHepatic: Increased serum ALT (6%)\\nHypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\\nImmunologic: Immune reconstitution syndrome\\nInfection: Viral infection (5%)\\nMiscellaneous: Fever and chills (6%)\\nNeuromuscular & skeletal: Increased creatine phosphokinase (7%)\\nRespiratory: ENT infection (5%)\\n<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\\nContraindications\\nHypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment. Canadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\\nWarnings/Precautions\\nConcerns related to adverse effects:\\n• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).'},\n",
       " {'sentence': 'Canadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\\nWarnings/Precautions\\nConcerns related to adverse effects:\\n• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).',\n",
       "  'index': 37,\n",
       "  'combined_sentence': 'Central nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\\nDermatologic: Skin rash (5%)\\nEndocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\\nGastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\\nHematologic & oncologic: Neutropenia (5%)\\nHepatic: Increased serum ALT (6%)\\nHypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\\nImmunologic: Immune reconstitution syndrome\\nInfection: Viral infection (5%)\\nMiscellaneous: Fever and chills (6%)\\nNeuromuscular & skeletal: Increased creatine phosphokinase (7%)\\nRespiratory: ENT infection (5%)\\n<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\\nContraindications\\nHypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment. Canadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\\nWarnings/Precautions\\nConcerns related to adverse effects:\\n• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance). • Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL).'},\n",
       " {'sentence': '• Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL).',\n",
       "  'index': 38,\n",
       "  'combined_sentence': 'Canadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\\nWarnings/Precautions\\nConcerns related to adverse effects:\\n• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance). • Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL). Frequent complete blood counts are recommended in patients with advanced HIV-1 disease.'},\n",
       " {'sentence': 'Frequent complete blood counts are recommended in patients with advanced HIV-1 disease.',\n",
       "  'index': 39,\n",
       "  'combined_sentence': '• Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL). Frequent complete blood counts are recommended in patients with advanced HIV-1 disease. Dosage interruption may be needed if anemia or neutropenia develops.'},\n",
       " {'sentence': 'Dosage interruption may be needed if anemia or neutropenia develops.',\n",
       "  'index': 40,\n",
       "  'combined_sentence': 'Frequent complete blood counts are recommended in patients with advanced HIV-1 disease. Dosage interruption may be needed if anemia or neutropenia develops. • Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir).'},\n",
       " {'sentence': '• Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir).',\n",
       "  'index': 41,\n",
       "  'combined_sentence': 'Dosage interruption may be needed if anemia or neutropenia develops. • Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir). Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.'},\n",
       " {'sentence': 'Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele.',\n",
       "  'index': 42,\n",
       "  'combined_sentence': '• Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir). Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment.'},\n",
       " {'sentence': 'All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment.',\n",
       "  'index': 43,\n",
       "  'combined_sentence': 'Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment. Discontinue Trizivir if a hypersensitivity reaction is suspected.'},\n",
       " {'sentence': 'Discontinue Trizivir if a hypersensitivity reaction is suspected.',\n",
       "  'index': 44,\n",
       "  'combined_sentence': 'All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment. Discontinue Trizivir if a hypersensitivity reaction is suspected. Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir.'},\n",
       " {'sentence': 'Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir.',\n",
       "  'index': 45,\n",
       "  'combined_sentence': 'Discontinue Trizivir if a hypersensitivity reaction is suspected. Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir. Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy.'},\n",
       " {'sentence': 'Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy.',\n",
       "  'index': 46,\n",
       "  'combined_sentence': 'Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir. Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy. Such reactions can occur within hours.'},\n",
       " {'sentence': 'Such reactions can occur within hours.',\n",
       "  'index': 47,\n",
       "  'combined_sentence': 'Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy. Such reactions can occur within hours. Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record.'},\n",
       " {'sentence': 'Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record.',\n",
       "  'index': 48,\n",
       "  'combined_sentence': 'Such reactions can occur within hours. Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record. Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2015).'},\n",
       " {'sentence': 'Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2015).',\n",
       "  'index': 49,\n",
       "  'combined_sentence': 'Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record. Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2015). These reactions usually include signs or symptoms in 2 or more of the following groups: fever; rash; gastrointestinal (eg, nausea, vomiting, diarrhea, abdominal pain); constitutional (eg, generalized malaise, fatigue, achiness); respiratory (eg, dyspnea, cough, pharyngitis).'}]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentences[:50]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "embeddings = oaiembeds.embed_documents([x['combined_sentence'] for x in sentences])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "for i, sentence in enumerate(sentences):\n",
    "    sentence['combined_sentence_embedding'] = embeddings[i]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "def calculate_cosine_distances(sentences):\n",
    "    distances = []\n",
    "    for i in range(len(sentences) - 1):\n",
    "        embedding_current = sentences[i]['combined_sentence_embedding']\n",
    "        embedding_next = sentences[i + 1]['combined_sentence_embedding']\n",
    "        \n",
    "        # Calculate cosine similarity\n",
    "        similarity = cosine_similarity([embedding_current], [embedding_next])[0][0]\n",
    "        \n",
    "        # Convert to cosine distance\n",
    "        distance = 1 - similarity\n",
    "\n",
    "        # Append cosine distance to the list\n",
    "        distances.append(distance)\n",
    "\n",
    "        # Store distance in the dictionary\n",
    "        sentences[i]['distance_to_next'] = distance\n",
    "\n",
    "    # Optionally handle the last sentence\n",
    "    # sentences[-1]['distance_to_next'] = None  # or a default value\n",
    "\n",
    "    return distances, sentences\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "distances, sentences = calculate_cosine_distances(sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[0.004241572587862508, 0.06501894226635085, 0.02820002984689285]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "distances[:3]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "plt.plot(distances);"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import numpy as np\n",
    "\n",
    "plt.plot(distances)\n",
    "\n",
    "y_upper_bound = .2\n",
    "plt.ylim(0, y_upper_bound)\n",
    "plt.xlim(0, len(distances))\n",
    "\n",
    "# We need to get the distance threshold that we'll consider an outlier\n",
    "# We'll use numpy .percentile() for this\n",
    "breakpoint_percentile_threshold = 90\n",
    "breakpoint_distance_threshold = np.percentile(distances, breakpoint_percentile_threshold) # If you want more chunks, lower the percentile cutoff\n",
    "plt.axhline(y=breakpoint_distance_threshold, color='r', linestyle='-');\n",
    "\n",
    "# Then we'll see how many distances are actually above this one\n",
    "num_distances_above_theshold = len([x for x in distances if x > breakpoint_distance_threshold]) # The amount of distances above your threshold\n",
    "plt.text(x=(len(distances)*.01), y=y_upper_bound/50, s=f\"{num_distances_above_theshold + 1} Chunks\");\n",
    "\n",
    "# Then we'll get the index of the distances that are above the threshold. This will tell us where we should split our text\n",
    "indices_above_thresh = [i for i, x in enumerate(distances) if x > breakpoint_distance_threshold] # The indices of those breakpoints on your list\n",
    "\n",
    "# Start of the shading and text\n",
    "# colors = ['b', 'g', 'r', 'c', 'm', 'y', 'k', 'orange', 'purple', 'brown', 'pink', 'gray', 'olive', 'lightblue']\n",
    "colors = ['b', 'g']\n",
    "for i, breakpoint_index in enumerate(indices_above_thresh):\n",
    "    start_index = 0 if i == 0 else indices_above_thresh[i - 1]\n",
    "    end_index = breakpoint_index if i < len(indices_above_thresh) - 1 else len(distances)\n",
    "\n",
    "    plt.axvspan(start_index, end_index, facecolor=colors[i % len(colors)], alpha=0.25)\n",
    "    plt.text(x=np.average([start_index, end_index]),\n",
    "             y=breakpoint_distance_threshold + (y_upper_bound)/ 20,\n",
    "             s=f\"Chunk #{i}\", horizontalalignment='center',\n",
    "             rotation='vertical')\n",
    "\n",
    "# # Additional step to shade from the last breakpoint to the end of the dataset\n",
    "if indices_above_thresh:\n",
    "    last_breakpoint = indices_above_thresh[-1]\n",
    "    if last_breakpoint < len(distances):\n",
    "        plt.axvspan(last_breakpoint, len(distances), facecolor=colors[len(indices_above_thresh) % len(colors)], alpha=0.25)\n",
    "        plt.text(x=np.average([last_breakpoint, len(distances)]),\n",
    "                 y=breakpoint_distance_threshold + (y_upper_bound)/ 20,\n",
    "                 s=f\"Chunk #{i+1}\",\n",
    "                 rotation='vertical')\n",
    "\n",
    "plt.title(\"Chunks Based On Embedding Breakpoints\")\n",
    "plt.xlabel(\"Index of sentences in the document\")\n",
    "plt.ylabel(\"Cosine distance between sequential sentences\")\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Initialize the start index\n",
    "start_index = 0\n",
    "\n",
    "# Create a list to hold the grouped sentences\n",
    "chunks = []\n",
    "\n",
    "# Iterate through the breakpoints to slice the sentences\n",
    "for index in indices_above_thresh:\n",
    "    # The end index is the current breakpoint\n",
    "    end_index = index\n",
    "\n",
    "    # Slice the sentence_dicts from the current start index to the end index\n",
    "    group = sentences[start_index:end_index + 1]\n",
    "    combined_text = ' '.join([d['sentence'] for d in group])\n",
    "    chunks.append(combined_text)\n",
    "    \n",
    "    # Update the start index for the next group\n",
    "    start_index = index + 1\n",
    "\n",
    "# The last group, if any sentences remain\n",
    "if start_index < len(sentences):\n",
    "    combined_text = ' '.join([d['sentence'] for d in sentences[start_index:]])\n",
    "    chunks.append(combined_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Chunk #0\n",
      "Abacavir, lamivudine, and zidovudine: Drug information (For additional information see \"Abacavir, lamivudine, and zidovudine: Patient drug information\" and see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\") For abbreviations and symbols that may be used in Lexicomp (show table) ALERT: US Boxed Warning\n",
      "Hypersensitivity reactions:\n",
      "Serious and sometimes fatal hypersensitivity reactions, with multiple organ involvement, have occurred with abacavir. Patients who carry the HLA-B*5701 allele are at a higher risk of a hypersensitivity reaction to abacavir; although, hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. Abacavir/lamivudine/zidovudine is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLA-B*5701-positive patients. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with abacavir/lamivudine/zidovudine or reinitiation of therapy with abacavir/lamivudine/zidovudine, unless patients have a previously documented HLA-B*5701 allele assessment. Discontinue abacavir/lamivudine/zidovudine immediately if a hypersensitivity reaction is suspected, regardless of HLA-B*5701 status and even when other diagnoses are possible. Following a hypersensitivity reaction to abacavir, never restart abacavir/lamivudine/zidovudine or any other abacavir-containing product because more severe symptoms, including death, can occur within hours. Similar severe reactions have also occurred rarely following the reintroduction of abacavir-containing products in patient who have no history of abacavir hypersensitivity. Hematologic toxicity:\n",
      "Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV-1 disease. Myopathy:\n",
      "Prolonged use of zidovudine has been associated with symptomatic myopathy. Lactic acidosis and severe hepatomegaly with steatosis:\n",
      "Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. Discontinue abacavir/lamivudine/zidovudine if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur. Exacerbations of hepatitis B:\n",
      "Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with hepatitis B virus (HBV) and HIV-1 and have discontinued lamivudine, which is one component of abacavir/lamivudine/zidovudine. Monitor hepatic function closely with both clinical and laboratory follow-up for at least several months in patients who discontinue abacavir/lamivudine/zidovudine and are coinfected with HIV-1 and HBV.\n",
      "\n",
      "\n",
      "Chunk #1\n",
      "If appropriate, initiation of anti-HBV therapy may be warranted. Brand Names: US\n",
      "Trizivir\n",
      "Brand Names: Canada\n",
      "Pharmacologic Category\n",
      "Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)\n",
      "Dosing: Adult\n",
      "HIV-1 infection, treatment: Oral: One tablet twice daily. Dosing: Pediatric(For additional information see \"Abacavir, lamivudine, and zidovudine: Pediatric drug information\")\n",
      "HIV-1 infection, treatment: Children and Adolescents ≥40 kg: Refer to adult dosing. Note: Not recommended for pediatric patients <40 kg.\n",
      "\n",
      "\n",
      "Chunk #2\n",
      "Dosing: Geriatric\n",
      "Refer to adult dosing. Dosing: Renal Impairment\n",
      "CrCl ≥50 mL/minute: No dosage adjustment necessary. CrCl <50 mL/minute: Use is not recommended (use dose-adjusted individual components). Dosing: Hepatic Impairment\n",
      "Mild impairment (Child-Pugh class A): Use is not recommended (use dose-adjusted individual components). Moderate to severe hepatic impairment (Child-Pugh Class B or C): Use is contraindicated.\n",
      "\n",
      "\n",
      "Chunk #3\n",
      "Dosage Forms\n",
      "Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Tablet, Oral:\n",
      "Trizivir: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg [contains fd&c blue #2 (indigotine)]\n",
      "Generic: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg\n",
      "Generic Equivalent Available (US)\n",
      "Yes\n",
      "Medication Guide and/or Vaccine Information Statement (VIS)\n",
      "An FDA-approved patient medication guide, which is available with the product information and at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf#page=32, must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.\n",
      "\n",
      "\n",
      "Chunk #4\n",
      "Administration\n",
      "Administer without regard to food.\n",
      "\n",
      "\n",
      "Chunk #5\n",
      "Hazardous Drugs Handling Considerations\n",
      "Hazardous agent (NIOSH 2016 [group 2]). Abacavir is a hazardous agent. Use appropriate precautions for receiving, handling, administration, and disposal.\n",
      "\n",
      "\n",
      "Chunk #6\n",
      "Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Use\n",
      "HIV infection: Treatment of HIV-1 infection alone or in combination with other antiretroviral agents.\n",
      "\n",
      "\n",
      "Chunk #7\n",
      "Limitations of use: Limited data exist on use alone in patients with higher baseline viral load levels (>100,000 copies/mL). Medication Safety Issues\n",
      "High alert medication:\n",
      "This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error. Adverse Reactions\n",
      "See individual agents as well as other combination products for additional information.\n",
      "\n",
      "\n",
      "Chunk #8\n",
      "Frequency not always defined. Central nervous system: Headache (13%), fatigue (12%), malaise (12%), depression (6%), anxiety (5%)\n",
      "Dermatologic: Skin rash (5%)\n",
      "Endocrine & metabolic: Increased amylase (2%), increased serum triglycerides (grade 3-4: 2%), increased gamma-glutamyl transferase, redistribution of body fat\n",
      "Gastrointestinal: Nausea (19%), nausea and vomiting (10%), diarrhea (7%), pancreatitis\n",
      "Hematologic & oncologic: Neutropenia (5%)\n",
      "Hepatic: Increased serum ALT (6%)\n",
      "Hypersensitivity: Hypersensitivity (1% to 9%; based on abacavir component; higher risk in carriers of the HLA-B*5701 allele)\n",
      "Immunologic: Immune reconstitution syndrome\n",
      "Infection: Viral infection (5%)\n",
      "Miscellaneous: Fever and chills (6%)\n",
      "Neuromuscular & skeletal: Increased creatine phosphokinase (7%)\n",
      "Respiratory: ENT infection (5%)\n",
      "<1%, postmarketing, and/or case reports: Abdominal pain, abnormal breath sounds, allergic sensitization (including anaphylaxis), alopecia, anemia, anorexia, aplastic anemia, arthralgia, cardiomyopathy, decreased appetite, dizziness, dyspepsia, erythema multiforme, exacerbation of hepatitis B (posttreatment), gynecomastia, increased serum bilirubin, increased serum transaminases, insomnia, lactic acidosis, liver steatosis, lymphadenopathy, myalgia, myasthenia, oral mucosa hyperpigmentation, paresthesia, peripheral neuropathy, rhabdomyolysis, seizure, sleep disorder, splenomegaly, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, urticaria, vasculitis, weakness, wheezing\n",
      "Contraindications\n",
      "Hypersensitivity to abacavir, lamivudine, zidovudine, or any component of the formulation; patients positive for HLA-B*5701 allele; moderate or severe hepatic impairment. Canadian labeling: Additional contraindications (not in US labeling): Hepatic impairment (regardless of severity of impairment); ANC <750 cells/mm3; hemoglobin <7.5 g/dL or 4.65 mmol/L\n",
      "Warnings/Precautions\n",
      "Concerns related to adverse effects:\n",
      "• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance). • Hematologic toxicity: [US Boxed Warning]: Zidovudine has been associated with hematologic toxicities (eg, neutropenia, anemia); use with caution in patients with bone marrow compromise (eg, granulocyte count <1,000 cells/mm3 or hemoglobin <9.5 g/dL). Frequent complete blood counts are recommended in patients with advanced HIV-1 disease.\n",
      "\n",
      "\n",
      "Chunk #9\n",
      "Dosage interruption may be needed if anemia or neutropenia develops. • Hypersensitivity reactions: [US Boxed Warning]: Serious hypersensitivity reactions (sometimes fatal) have occurred in patients taking abacavir (in Trizivir). Patients who carry the HLA-B*5701 allele are at a higher risk for a hypersensitivity reaction to abacavir, although hypersensitivity reactions have occurred in patients who do not carry the HLA-B*5701 allele. All patients should be screened for the HLA-B*5701 allele prior to initiating therapy with Trizivir or reinitiation of therapy with Trizivir unless patients have had a previously documented HLA-B*5701 allele assessment. Discontinue Trizivir if a hypersensitivity reaction is suspected. Trizivir is contraindicated in patients who have the HLA-B*5701 allele or in patients with a prior hypersensitivity reaction to abacavir. Reintroduction of Trizivir or any other abacavir-containing product can result in life-threatening or fatal hypersensitivity reactions, even in patients who have no history of hypersensitivity to abacavir therapy. Such reactions can occur within hours. Additionally, allele-positive patients (including abacavir treatment naive) should have an allergy to abacavir documented in their medical record. Reactions usually occur within 9 days of starting abacavir; ~90% occur within 6 weeks, although these reactions may occur at any time during therapy (HHS [adult] 2015). These reactions usually include signs or symptoms in 2 or more of the following groups: fever; rash; gastrointestinal (eg, nausea, vomiting, diarrhea, abdominal pain); constitutional (eg, generalized malaise, fatigue, achiness); respiratory (eg, dyspnea, cough, pharyngitis).\n",
      "\n",
      "\n",
      "Chunk #10\n",
      "Other signs and symptoms include lethargy, headache, myalgia, edema, abnormal chest x-ray findings, arthralgia and paresthesia. Anaphylaxis, liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, myolysis, and death have occurred in association with hypersensitivity reactions. Physical findings (lymphadenopathy, mucous membrane lesions, and rash [maculopapular, urticarial or variable]) may occur. Erythema multiforme has also been reported.\n",
      "\n",
      "\n",
      "Chunk #11\n",
      "Laboratory abnormalities (eg, elevated liver function tests, elevated creatine phosphokinase, elevated creatinine, and lymphopenia) may occur. Trizivir should be permanently discontinued if hypersensitivity cannot be ruled out, even when other diagnoses are possible. Following a hypersensitivity reaction, Trizivir SHOULD NOT be restarted because more severe symptoms may occur within hours, including LIFE-THREATENING HYPOTENSION AND DEATH. If Trizivir is to be restarted following an interruption in therapy not associated with symptoms of a hypersensitivity reaction, carefully evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or cannot be ruled out regardless of HLA-B*5701 status. If Trizivir is restarted, continually monitor for symptoms of a hypersensitivity reaction. Make the patient aware that reintroduction should only take place if medical care is readily accessible. • Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves’ disease, polymyositis, Guillain-Barré syndrome) later in therapy; further evaluation and treatment may be required. • Lactic acidosis/hepatomegaly: [US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues; use with caution in patients with risk factors for liver disease (risk may be increased with female gender, obesity, pregnancy or prolonged exposure) and suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis). • Myopathy: [US Boxed Warning]: Prolonged use of zidovudine has been associated with symptomatic myopathy and myositis. • Pancreatitis: Pancreatitis has been observed with abacavir, lamivudine and zidovudine; rule out pancreatitis in patients who develop signs/symptoms (eg, nausea/vomiting, abdominal pain, elevated lipase and amylase) during therapy. Disease-related concerns:\n",
      "• Chronic hepatitis B: [US Boxed Warning]: Exacerbation of hepatitis B (including fatalities) has been reported with discontinuation of lamivudine in coinfected HIV/HBV patients; monitor hepatic function (eg, serum ALT) and HBV viral DNA closely for several months after discontinuing Trizivir in coinfected patients. • Coronary heart disease: Use has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use. • Lamivudine-resistant HBV: Emergence of HBV virus variants associated with resistance to lamivudine have been reported in HIV-1 infected subjects who have received lamivudine-containing antiretroviral regimens in the presence of HBV coinfection. • Renal impairment: Trizivir, as a fixed-dose combination tablet, should not be used in patients with CrCl <50 mL/minute. Concurrent drug therapy issues:\n",
      "• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Special populations:\n",
      "• Pediatric patients <40 kg: Trizivir, as a fixed-dose combination tablet, should not be used in patients <40 kg or those requiring dosage adjustment. • Therapy-experienced patients: Patients with prolonged prior nucleoside reverse transcriptase inhibitor (NRTI) exposure or presence of HIV-1 isolates containing multiple mutations conferring resistance to NRTIs have limited response to abacavir. The potential for cross resistance between abacavir and other NRTIs should be considered when evaluating new regimens in therapy experienced patients. Metabolism/Transport Effects\n",
      "Refer to individual components. Drug Interactions (For additional information: Launch drug interactions program) Acemetacin: May enhance the adverse/toxic effect of Zidovudine. Specifically, the risk for hematologic toxicity may be increased. Risk C: Monitor therapy\n",
      "Acyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine. Risk C: Monitor therapy\n",
      "Amodiaquine: Zidovudine may enhance the neutropenic effect of Amodiaquine. Risk X: Avoid combination\n",
      "BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination\n",
      "Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. Risk C: Monitor therapy\n",
      "Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy\n",
      "Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction. Risk D: Consider therapy modification\n",
      "CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy\n",
      "Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Risk X: Avoid combination\n",
      "Dexketoprofen: May enhance the adverse/toxic effect of Zidovudine. Risk C: Monitor therapy\n",
      "Trimethoprim: May increase the serum concentration of LamiVUDine. Risk C: Monitor therapy\n",
      "Valproate Products: May increase the serum concentration of Zidovudine. Risk C: Monitor therapy\n",
      "Food Interactions\n",
      "Ethanol decreases the elimination of abacavir and may increase the risk of toxicity. Management: Monitor patients. Pregnancy Implications\n",
      "The Health and Human Services (HHS) Perinatal HIV Guidelines generally do not recommend this combination as initial therapy in antiretroviral-naive pregnant females due to inferior virologic activity. However, females who become pregnant on this regimen, in absence of other antiretroviral medications, may continue if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated (HHS [perinatal] 2017). See individual agents. Breast-Feeding Considerations\n",
      "Abacavir, lamivudine, and zidovudine are present in breast milk. See individual agents. Monitoring Parameters\n",
      "Blood glucose, CBC with differential, serum creatine kinase, CD4 count, HIV RNA plasma levels, bilirubin, serum transaminases, triglycerides, serum amylase; HLA-B*5701 genotype status prior to initiation of therapy and prior to reinitiation of therapy in patients of unknown HLA-B*5701 status; signs and symptoms of hypersensitivity, particularly in patients untested for the HLA-B*5701 allele; signs and symptoms of pancreatitis; observe for appearance of opportunistic infections\n",
      "Mechanism of Action\n",
      "The combination of abacavir, lamivudine, and zidovudine is believed to act synergistically to inhibit reverse transcriptase via DNA chain termination after incorporation of the nucleoside analogue as well as to delay the emergence of mutations conferring resistance. Pharmacodynamics/Kinetics\n",
      "Bioavailability studies of Trizivir® show no difference in AUC or Cmax when compared to abacavir, lamivudine, and zidovudine given together as individual agents. See individual agents. Pricing: US\n",
      "Tablets (Abacavir-Lamivudine-Zidovudine Oral)\n",
      "300-150-300 mg (60): $1,738.46\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for i, chunk in enumerate(chunks):\n",
    "    buffer = 200\n",
    "    \n",
    "    print (f\"Chunk #{i}\")\n",
    "    # print (chunk[:buffer].strip())\n",
    "    # print (\"...\")\n",
    "    # print (chunk[-buffer:].strip())\n",
    "    print(chunk)\n",
    "    print (\"\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "cs-5787",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.20"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
